Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients
- 1 July 1997
- journal article
- clinical trial
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 171 (1) , 73-77
- https://doi.org/10.1192/bjp.171.1.73
Abstract
BACKGROUND Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions. METHOD In order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day). RESULTS For all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe. CONCLUSION This study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.Keywords
This publication has 9 references indexed in Scilit:
- Comparison of acamprosate and placebo in long-term treatment of alcohol dependenceThe Lancet, 1996
- Naltrexone in the Treatment of Alcohol DependenceArchives of General Psychiatry, 1992
- Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised ratsPharmacology Biochemistry and Behavior, 1992
- ACAMPROSATE AND DIAZEPAM DIFFERENTIALLY MODULATE ALCOHOL-INDUCED BEHAVIOURAL AND CORTICAL ALTERATIONS IN RATS FOLLOWING CHRONIC INHALATION OF ETHANOL VAPOURAlcohol and Alcoholism, 1991
- Long‐Term Recovery in AlcoholicsAlcohol, Clinical and Experimental Research, 1989
- The effect of type of aftercare follow-up on treatment outcome among alcoholics.Journal of Studies on Alcohol, 1988
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959